Get startedLog in
    Picture of Shandong Xinhua Pharmaceutical Co logo

    719 — Shandong Xinhua Pharmaceutical Co Income Statement

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareAdventurousMid CapContrarian
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Shandong Xinhua Pharmaceutical Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

    2020
    December 31st
    2021
    December 31st
    R2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    CAS
    CAS
    CAS
    CAS
    CAS
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue6,0066,5607,5038,1018,466
    Cost of Revenue
    Gross Profit1,7681,7401,9942,3281,990
    Selling / General / Administrative Expenses
    Research And Development
    Depreciation and Amortization
    Unusual Expense / Income
    Other Operating Expenses
    Total Operating Expenses5,5886,1367,0297,5717,937
    Operating Profit418424474530529
    Other Net Non Operating Costs
    Net Income Before Taxes412421472533534
    Provision for Income Taxes
    Net Income After Taxes347362426506487
    Minority Interest
    Net Income Before Extraordinary Items
    Net Income325349411497470
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income325349411497470
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS0.5320.5630.6250.7290.691
    Dividends per Share